498 related articles for article (PubMed ID: 25974251)
1. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Jung YS; Park DI; Kim YH; Lee JH; Seo PJ; Cheon JH; Kang HW; Kim JW
J Gastroenterol Hepatol; 2015 Dec; 30(12):1705-12. PubMed ID: 25974251
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.
Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro D; Benítez Roldán A; Merino V; Ramírez G; Caunedo Álvarez A; Romero Gómez M
Dig Dis Sci; 2017 May; 62(5):1305-1312. PubMed ID: 28281165
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
5. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
Radin M; Sciascia S; Roccatello D; Cuadrado MJ
BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
[TBL] [Abstract][Full Text] [Related]
6. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.
Kang YS; Moon HH; Lee SE; Lim YJ; Kang HW
Dig Dis Sci; 2015 Apr; 60(4):951-6. PubMed ID: 25326115
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
[TBL] [Abstract][Full Text] [Related]
9. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease.
Kim ES; Choi S; Choe BH; Park S; Lee YJ; Sohn SJ; Kim SC; Kang KS; Lee K; Shim JO; Kim YB; Hong SJ; Lee YM; Kim HJ; Choi SY; Kim JY; Lee Y; Park JS; Kim JY; Yi DY; Lee JH; Choi KH; Jang HJ; Jeong IS; Kang B
Front Immunol; 2024; 15():1284181. PubMed ID: 38455036
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
11. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Molnár T
Expert Opin Biol Ther; 2015; 15(9):1257-62. PubMed ID: 26134250
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L; Peyrin-Biroulet L
Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
[TBL] [Abstract][Full Text] [Related]
15. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
16. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn's disease.
Oike T; Akizue N; Ohta Y; Koseki H; Saito M; Yokoyama Y; Imai Y; Taida T; Okimoto K; Saito K; Ogasawara S; Matsumura T; Nakagawa T; Arai M; Katsuno T; Fukuda Y; Kitsukawa Y; Kato J; Kato N
Arab J Gastroenterol; 2024 May; ():. PubMed ID: 38714472
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
19. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
20. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
